# Entera Bio Ltd. (ENTX)

> Source: Nexqual · https://nexqual.com/ENTX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Entera Bio Ltd. (ENTX), nexqual.com/ENTX" · informational, not investment advice.

**Price:** USD 3.02 (-0.98% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 3.05 · day 2.92–3.04 · 52w 0.91–4.2 · market cap $525M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$17.0M, free cash flow -$11.0M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 9.75 (range 9–11).
- Total return with dividends: 1Y +41.1% vs S&P 500 +14.9%; 5Y -29.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-13, EPS estimate USD -0.07, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $571K | $134K | $0K | $181K | $42K | $0K |
| Gross profit | $198K | $33K | $0K | $9K | $0K | — |
| Operating income | -$12.2M | -$13.0M | -$8.9M | -$9.6M | -$11.5M | -$14.4M |
| Net income | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M | -$17.0M |
| EPS (diluted) | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 | — |
| Free cash flow | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M | -$11.0M |
| Gross margin | 34.7% | 24.6% | — | 5.0% | 0.0% | — |
| Operating margin | -2139.6% | -9714.2% | — | -5295.6% | -27450.0% | — |
| Net margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% | — |
| Revenue growth | +56.4% | -76.5% | -100.0% | — | -76.8% | — |
| Cash + short-term investments | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 72.3x · FCF yield -2.09% · Earnings yield -3.24%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 9.75 (low 9, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | Guggenheim | Initiated | Buy | $11 |
| 2026-09-23 | LifeSci Capital | Initiated | Outperform | $10 |
| 2026-09-22 | Cantor Fitzgerald | Initiated | Overweight |  |
| 2026-09-18 | Leerink Partners | Initiated | Outperform | $9 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +41.1% | -29.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +41.3% | -6.7% |
| Volatility (annualized) | 109.5% | 85.3% |
| Max drawdown | -68.2% (Nov 2025→Mar 2026) | -88.3% (Oct 2021→Nov 2022) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/ENTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ENTX's own 10-K filed 2026-03-27 (https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/zk2634461.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | OPKO HEALTH, INC. (OPK) | "In December 2025, we announced new in vivo PK/PD data supporting the development of a proprietary long-acting PTH (LA-PTH) analog, which is being developed as part of a material transfer and collaboration agreement with …" |
| Partner | OPKO Biologics | "In September 2023, we entered into the 2023 Collaboration Agreement with OPKO Biologics." |
| Partner | Oramed | "In 2011, we entered into a patent transfer agreement with Oramed Ltd. ("Oramed"), which we refer to as the Patent Transfer Agreement, pursuant to which Oramed assigned to us all of its rights, title and interest in the p…" |
| Partner | Oramed NewCo | "On March 27, 2025, we entered into a Novation Agreement with Oramed, and Oramed NewCo Inc. ("Oramed NewCo") pursuant to which Oramed NewCo replaced Oramed as a party to the Patent Transfer Agreement." |
| Partner | Unihead Biopark | "Under a lease agreement with Unihead Biopark Ltd., we lease approximately 622 square meters of office and laboratory space." |
| Partner | Leerink Partners | "On September 2, 2022, we entered into a Sales Agreement with Leerink Partners LLC (f/k/a SVB Securities LLC), as sales agent, to implement an ATM program (the "Leerink ATM Program") under which we were originally able to…" |
| Partner | SVB Securities | "On September 2, 2022, we entered into a Sales Agreement with Leerink Partners LLC (f/k/a SVB Securities LLC), as sales agent, to implement an ATM program (the "Leerink ATM Program") under which we were originally able to…" |
| Partner | Sanofi (SNY) | "She currently serves as the Head of Sanofi's Strategic Partnership and Portfolio Planning where she is responsible for increasing franchise growth and profitability." |

Other companies that name ENTX in their own reports (relationship from ENTX's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | OPKO HEALTH, INC. (OPK) | 10-K 2026-02-26 | "OPK-88006 (Oral): In collaboration with Entera Bio Ltd. ("Entera"), we are advancing a once-daily tablet formulation of OPK-88006." |

## Company outlook (8-K filed 2026-08-07)

- "Entera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028. ·"
- "EB618 was well tolerated at doses exceeding the anticipated clinical dose range by more than tenfold."
- "As previously disclosed, Entera expects to evaluate the initiation of EB618 clinical development pursuant to analysis of the Phase 1 SAD/MAD studies of subcutaneous injectable OXM being conducted by OPKO."
- "The net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through the anticipated submission of NDA to the FDA, advance EB612 into the clinic in collaboration with OPKO and extend the Company's cash runway into 2030. ·"

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.07 | $-0.08 | -15.0% | $0 | 5 |
| Next quarter (ends 2026-12-31) | $-0.14 | $-0.09 | +53.3% | $0 | 5 |
| Current fiscal year (ends 2026-12-31) | $-0.40 | $-0.34 | +18.2% | $0 | 5 |
| Next fiscal year (ends 2027-12-31) | $-0.42 | $-0.57 | -26.3% | $0 | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-13): ±38.1%; last 8 reports averaged ±5.4%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 151.3% | ±38.1% |
| 2027-02-19 | 119 | 175.2% | ±93.7% |